spacer
home > ebr > spring 2017 > managing e&l unknown compounds
PUBLICATIONS
European Biopharmaceutical Review

Managing E&L Unknown Compounds

Unknown compound characterisation has always been one of the most challenging aspects of analytical chemistry. Despite the difficulties, this identification is critical for a meaningful extractables and leachables (E&L) evaluation of container closure systems; single-use systems; drug delivery and combination products; and medical devices.

Identification of unknown extractable compounds is key to a successful E&L study due to the fact that there is no universally established concentration limit for leachable compounds. As a result, a toxicological risk assessment based on the intended dosing regimen of the product is required to determine if a potential leachable compound poses a risk to patient safety. Unfortunately, accurate and meaningful toxicological assessments are not possible for unknown compounds. These are typically assessed using a worst case scenario, where they are evaluated as extremely toxic this however often leads to applying an inaccurate level of risk. Therefore, a systematic approach for the characterisation of unknown extractable compounds is essential to enable scientists to assign the correct degree of toxicological concern to a given analyte.

So, how does one go about identifying an unknown compound? The use of the proper instrumentation is critical. High resolution mass spectrometers that enable an accurate mass determination to at least three decimal places such as liquid chromatographyquadrupole time of flights (LC-QTOFs) and gas chromatography (GC)-QTOFs are suitable for this purpose and their use generates a plethora of data that can often lead to the identification of an empirical formula or class of compound for the unknown. This information can then be further evaluated with specialised software that is able to quickly search historical data and databases to provide a preliminary identification of the unknown extractable compound.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Simone Carrara, E&L Laboratory Manager; Andrew Blakinger, Manager, Extractables & Leachables Testing; Thomas Lehman, PhD, Director, Method Development and Validation and Extractables and Leachables, Eurofins BioPharma Product Testing
spacer
Simone Carrara
spacer
spacer
spacer
Andrew Blakinger
spacer
spacer
spacer
Thomas Lehman
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

1 Billion Savings Opportunity and Value to the UK Economy from SBRI Healthcare Innovation Programme

An NHS England funded initiative to develop products that address unmet health needs, today released its annual report that shows how the programme has created a pipeline of innovations that could bring the NHS 1 billion of savings.
More info >>

White Papers

Trial Timelines

Thomson Reuters

Save resources with accurate trial length projections. How analytics based on curated content can deliver insight for clinical strategies.
More info >>

 
Industry Events

12th annual Cold Chain Distribution Conference and Exhibition

13-14 December 2017, Copthorne Tara Hotel, London, UK

Responding to the evolution within the industry, SMi is proud to announce the return of its leading 12th annual Cold Chain Distribution event. Returning to London in December, this year's event will remain at the forefront of innovation
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement